No Data
No Data
Pharmaron (03759.HK) held a board of directors meeting on August 27 to review and approve its mid-term performance.
Pharmaron (03759.HK) announced on August 14th that the board of directors meeting will be held on Tuesday, August 27th, 2024 to review and approve the interim performance of the company and its subsidiaries for the six months ended June 30th, 2024, which includes its release.
PHARMARON: NOTICE OF BOARD MEETING
Hong Kong stocks fluctuated | CXO concept stocks fell in early trading, Geopolitical game has yet to land, CXO industry prosperity still fluctuates.
CXO concept stocks fell in early trading. As of press time, Tigermed (03347) fell 5.89% to HKD 31.9; Pharmaron (03759) fell 4.04% to HKD 9.02; Wuxi AppTec (02359) fell 3.75% to HKD 33.35; and Frontage (01521) fell 1.35% to HKD 0.73.
Pharmaron (03759.HK) has completed industrial and commercial registration changes and issued a new business license.
Pharmaron (03759.HK) announced on August 12th that Pharmaron (Peking) New Drug Technology Co., Ltd. (hereinafter referred to as the 'Company') held the 2023 annual shareholders meeting, the 2024 first A-share category shareholders meeting, and the 2024 first H-share category shareholders meeting on June 6, 2024 to approve the Proposal 1 on increasing registered capital and revising the Company's Articles of Association, and Proposal 2 on increasing registered capital and revising the Company's Articles of Association. Recently, the company has completed the relevant industrial and commercial registration procedures and obtained the Beijing economic technology ...
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
No Data